Bluebird’s Zynteglo Approval Kicks Off Commercial Operations

Beta-Thalassemia Gene Therapy’s List Price Is $2.8m

 
• By Mandy Jackson
business people stacking cogwheels in team
Bluebird already has assembled the provider, payer and patient support pieces of its commercial operations • Source: Shutterstock

More from New Products

More from Scrip